Research from the United States has demonstrated how PV technology can be used to kill cancer cells. Although still at an embryonic stage, the findings of the study and initial test results ...

--Provectus today announced that H. Lee Moffitt Cancer Center will present non-clinical data from ongoing research on investigational autolytic cancer immunotherapy PV-10, an injectable ...

Provectus Biopharmaceuticals Announces Discovery of Unique PV-10®-Induced STING Pathway Mechanism for Presentation at American Association for Cancer Research (AACR) 2020 Virtual Annual Meeting II ...

Provectus Biopharmaceuticals Announces Presentation of Cancer Immunotherapy PV-10 Poster for HNSCC at AACR 2024 Annual Meeting ...

KNOXVILLE, TN, Nov. 06, 2023 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced that preclinical data from ongoing research on the potential use of investigational cancer immunotherapy PV ...

"Our studies have shown potential benefit of GLP-1 receptor agonists in polycythemia vera," he said. "Obviously, randomized ...

Polycythemia vera (PV) is a slow-growing blood cancer in which your body makes too many red blood cells. You may have it for years before you notice any symptoms. Most people find out they have PV ...

Many people with polycythemia vera (PV) live a normal life with this rare blood cancer under control. The goal is to avoid complications like blood clots, which may happen because PV thickens your ...

--Provectus today announced that data from an ongoing clinical trial of investigational cancer immunotherapy PV-10 for the treatment of neuroendocrine tumors metastatic to the liver refractory to ...